| |
Abstract |
| Title |
: Empiric antimicrobial therapy in cancer patients with febrile neutropenia complication in department of chemotherapy Sunpasitthiprasong Hospital, Ubonratchathani |
| By |
: Pitchayanun Chantra and Wareerat Wongsrikaew |
| Degree |
: DOCTOR OF PHARMACY |
| Advisor |
: Manit Saeteaw |
| Keywords |
: Febrile neutropenia, Cancer, Sunpasitthiprasong Hospital, Antimicrobial |
| |
|
| Febrile neutropenia (FN) is a serious complication leading to increase infection risk and mortality. Appropriated antimicrobial selection can improve treatment outcome in FN patient. Objectives: The purpose of this study was to evaluate theproportion and percentage of febrile neutropenia in cancer patients. Methods: The retrospective cohort study was conducted in cancer patients with febrile neutropeniain Sunpasitthiprasong Hospital, Ubonratchathani duringJanuary 2014 and August 2016.Descriptive statistic was applied for data interpretation. Mortality was reported in proportion and percentage. Results: There were 16,579 hospital visitsduring study period. 150 patients were diagnosed as febrile neutropenia (204 episodes). The incidence of FN was 0.95%. Of FN patients, the median of age was 38 years old. Mainly of patients were diagnosed as hematologic malignancies (76 percent). Blood culture could identify infection in 107 episodes (52.5 %). Ceftazidime combined with amikacin was the most selected empirical antimicrobial (40.7%). The antimicrobial appropriation according to IDSA guideline was found in 160 episodes (78.4%). 21 patients died during FN treatment. The mortality incidence was 14%.Conclusion: Febrile neutropenia (FN) incidence is 0.95%. Some patients die during treatment. The majority of empirical antimicrobial selections in hospital are appropriate according to IDSAguideline. |
| |
|
| Close this window |